The announcement of positive interim data from clinical studies is a significant milestone for a pharmaceutical company, especially in the context of rare diseases. This news is likely to increase investor confidence in Quoin Pharmaceuticals, potentially leading to a positive impact on the stock price. The relevance is high as the news directly pertains to the company's core operations and product development. The importance is also high due to the potential implications for future revenue and market position.